An interventional study of L-PRF and Standard Extraction in Osteoradionecrosis of the Jaw and Medicine Related Osteonecrosis of the Jaw, sponsored by Swansea Bay University Health Board. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-13.
Sponsored by Swansea Bay University Health Board · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Osteonecrosis with a site in United Kingdom — 5 open to participants now, 15 under way, none of them phase 3. Osteonecrosis · United Kingdom.
Among the 33 studies in Osteonecrosis with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2026, is one of 6 with no phase, reaches primary completion later than 4 of the 14 other live ones, and was the 33rd registered.
287 studies on the registry are indexed under Osteonecrosis; 46 are open to participants now.
Browse Osteonecrosis studies →5 of the 33 studies in Osteonecrosis with a site in United Kingdom are open now. Recruiting first, the newest first:
Stryker Trauma and Extremities · Sites in United Kingdom, United States, Canada and 2 more countries
Ages 18+
Exactech · Sites in United Kingdom, United States, Canada and 3 more countries
Ages 21+
MicroPort Orthopedics Inc. · Sites in United Kingdom, United States
Ages 21+
Texas Scottish Rite Hospital for Children · Sites in United Kingdom, United States, Australia and 12 more countries
Ages 1–18
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 23 Osteonecrosis studies recruiting now, 14 (61%) set no upper age limit and 4 (17%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 40 is below the median of 67 across 152 interventional studies indexed under Osteonecrosis.
Median enrollment 206 across the 14 interventional studies, 200 across the 19 observational. Of the 16 that completed or were terminated, 3 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 33 have an industry lead sponsor. The 10 most frequent:
Swansea Bay University Health Board is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
Swansea Bay University Health Board has 1 study filed under Osteonecrosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Osteonecrosis with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01480440Zimmer BiometOutcomes Study of the Trabecular Metal (TM) Reverse Shoulder System | 2026-12 |
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
| NCT07585123Swansea Bay University Health BoardL-PRF in Prevention of ORN and MRONJ Following Tooth Extractions;v3.0 | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Osteonecrosis with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Osteoradionecrosis (ORN) and medication-related osteonecrosis of the jaw (MRONJ) are debilitating complications following dental extractions in patients who have received head and neck radiotherapy or antiresorptive therapy. These conditions are associated with significant morbidity, including persistent pain, poor oral function, and reduced quality of life.
While preventive strategies remain limited, platelet-rich fibrin (L-PRF), an autologous fibrin matrix enriched with growth factors, has shown potential in promoting wound healing and modulating inflammation. This prospective, triple-blind, randomised pilot trial aims to evaluate the effectiveness of L-PRF in enhancing socket healing and reducing the incidence of ORN and MRONJ. Forty patients (20 post-radiotherapy, 20 on antiresorptive agents) undergoing non-surgical dental extractions will be randomised to receive either L-PRF or standard care. The primary outcome is mucosal healing at Day 10 post-extraction, assessed using the Landry wound healing index. Secondary outcomes include the incidence of ORN or MRONJ at extraction sites assessed at 9, 17, 25, and 52 weeks. This study aims to provide early evidence on the clinical utility of L-PRF in preventing osteonecrosis in high-risk patients.
Osteoradionecrosis (ORN) is a condition in which necrosis of the jawbone occurs in patients who have previously undergone radiotherapy for head and neck cancer. Medication-Related Osteonecrosis of the Jaw (MRONJ) occurs in patients receiving, or who have received, antiresorptive therapies such as bisphosphonates or denosumab. Both conditions share underlying mechanisms including impaired bone healing, chronic inflammation, and disrupted angiogenesis . Patients in either group face an increased risk of poor healing following tooth extraction, which can result in persistent pain, infection, and progressive jawbone necrosis. These complications profoundly impair patients' abilities to eat and speak, significantly reducing their quality of life.
ORN and MRONJ are extremely difficult to predict, prevent, and manage. Treatment typically requires removal of necrosed bone followed by complex reconstructive procedures that consume significant hospital resources, including materials, staff time, and prolonged hospital stays. Despite these interventions, patients often experience substantial reductions in quality of life. The economic burden on the NHS and responsible trusts is considerable, underscoring the urgent need for improved preventive approaches.
Leukocyte- and platelet- rich fibrin (L-PRF), an autologous leukocyte and platelet concentrate, has demonstrated promising results in promoting soft tissue and bone healing, owing to its angiogenic, anti-inflammatory, and regenerative properties . Its use in dental extractions could mitigate the risk of developing ORN or MRONJ in high-risk populations.
L-PRF is a second-generation platelet concentrate that releases growth factors such as PDGF, TGF-β, and VEGF over an extended period. In vitro studies show that its three-dimensional fibrin matrix continuously releases these factors and cytokines for up to 21 days, which helps regulate inflammation and promote angiogenesis, supporting tissue healing.
L-PRF, a second-generation platelet concentrate, has gained popularity in oral surgery and periodontal procedures (12) with evidence suggesting faster mucosal healing and reduced post-operative complications, because of a slower, continuous release of growth factors when compared to other concentrates in vitro. Furthermore, the leukocytes presented in L-PRF may synthesize several pro- and anti-inflammatory cytokines as well.
However, controlled data on its use specifically for ORN or MRONJ prevention is scarce. Small case series and observational studies suggest improved outcomes, but robust trial data is lacking.
Given the significant morbidity associated with ORN and MRONJ and the lack of proven preventive strategies, evaluating L-PRF in a clinical trial setting is justified. The intervention is autologous and low-risk. Potential benefits include enhanced mucosal healing and reduced incidence of osteonecrosis. Risks are minimal and largely relate to venepuncture or standard surgical procedures. The trial aims to determine feasibility, safety, and early efficacy signals to inform future large-scale trials.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-General Inclusion Criteria (Applies to All Participants)
Age ≥18 years
Requiring extraction of one or more teeth with hopeless prognosis
Capacity to provide
Ability and willingness to attend all scheduled follow-up visits over 12 months
-Post-Radiotherapy Group - Specific Inclusion
Previous radiotherapy to the head and neck region
Documented radiation dose ≥50 Gy
Radiotherapy records (dose, field, date) must be available
-Antiresorptive Group - Specific Inclusion
Current or prior use of antiresorptive agents (e.g. bisphosphonates or denosumab)
Medication history must be available in medical records
Exclusion Criteria:
Inability to maintain adequate oral hygiene due to motor disability
Uncontrolled systemic illness (e.g. uncontrolled diabetes)
Use of anticoagulants, , or medications known to impair healing
Requirement for surgical (complex) extractions
Enrolment in another clinical trial
Known allergy to anaesthetic agents, L-PRF components, or antibiotics used in perioperative protocol
Anticipated non-compliance with follow-up
-Post-Radiotherapy Group - Specific Exclusion
Previous or current antiresorptive therapy
History of re-irradiation or radiation dose \<50 Gy
-Antiresorptive Group - Specific Exclusion
History of head and neck radiotherapy
Neoplastic involvement of the jaws
Active untreated oral infection or pathology at time of planned extraction
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: L-PRF
Other: Standard Extraction
L-PRF is made from the patient's own blood and contains natural healing cells and growth factors. It is already used in other areas of dentistry to help wounds heal, but it is not yet clear whether it helps prevent jawbone necrosis in patients with a history of radiotherapy for head and cancers, or in patients taking antiresorptive medications. This study will help us understand whether using L-PRF during extractions makes healing faster and safer and can can prevent or reduce the chance of developing osteoradionecrosis or MRONJ in patients with a history of radiotherapy for head and cancers, or in patients taking antiresorptive medications respectively.
No L-PRF will be placed in the post-extraction sockets
Mucosal healing of the dental extraction, assessed using the Landry Wound Healing Index.
Time frame: Day !0
Incidence of ORN and MRONJ at the extraction sites
Time frame: assessed at 9, 17, 25 weeks and 12 months post-extraction.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Aug 2026; primary completion for Jul 2027, 11 months later.
Of 45 interventional studies with no phase under Osteonecrosis, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 91. This study's planned 11 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Swansea Bay University Health Board